A new publication involving dulaglutide was released on October 15, 2026. The paper, titled "Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis," appeared in the European Journal of Preventive Cardiology.
The publication is listed as an analysis from the SURPASS-CVOT trial, examining patients with diabetes, atherosclerotic cardiovascular disease, and heart failure who were treated with either tirzepatide or dulaglutide. This entry reflects the release of the publication itself, as indexed under PubMed ID 42875024.
No findings, results, or conclusions from the analysis are included in this brief. Readers interested in the specific outcomes reported should consult the full text of the publication directly.
For additional background on dulaglutide, including its approved regulatory status, readers can refer to the compound overview for further context.